. (2010) Erythro-9-(2-hydroxy-3-nonyl) We have discovered a novel way of blocking the spontaneous differentiation of hESCs in the absence of exogenous cytokines by supplementing feeder-free conditions with erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), an established inhibitor of adenosine deaminase (ADA) and cyclic nucleotide phosphodiesterase-2 (PDE2). hESCs maintained in feeder-free conditions with EHNA for more than 10 passages showed no reduction in hESC associated markers including NANOG, POU5F1 and SSEA 4 compared to cells maintained in feeder-free conditions containing basic fibroblast growth factor (bFGF). Spontaneous differentiation was reversibly suppressed by the addition of EHNA, but upon removing EHNA hESC populations underwent efficient spontaneous, multi-lineage and directed differentiation. EHNA also acts as a strong blocker of directed neuronal differentiation. Chemically distinct inhibitors of ADA and PDE2 lacked the capacity of EHNA to suppress hESC differentiation, suggesting that the effect is not driven by inhibition of either ADA or PDE2. Preliminary structure activity relationship analysis found the differentiation blocking properties of EHNA to reside in a pharmacophore comprised of a close adenine mimetic with an extended hydrophobic substituent in the 8-or 9-position. We conclude that EHNA and simple 9-alkyladenines can block directed neuronal and spontaneous differentiation in the absence of exogenous cytokine addition, and may provide a useful replacement for bFGF in large scale or cGMP compliant processes.
SYNOPSIS
Human embryonic stem cells (hESCs) have enormous potential for use in pharmaceutical development and therapeutics, however to realise this potential there is a requirement for simple and reproducible cell culture methods that provide adequate numbers of cells of suitable quality. We have discovered a novel way of blocking the spontaneous differentiation of hESCs in the absence of exogenous cytokines by supplementing feeder-free conditions with erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), an established inhibitor of adenosine deaminase (ADA) and cyclic nucleotide phosphodiesterase-2 (PDE2). hESCs maintained in feeder-free conditions with EHNA for more than 10 passages showed no reduction in hESC associated markers including NANOG, POU5F1 and SSEA 4 compared to cells maintained in feeder-free conditions containing basic fibroblast growth factor (bFGF). Spontaneous differentiation was reversibly suppressed by the addition of EHNA, but upon removing EHNA hESC populations underwent efficient spontaneous, multi-lineage and directed differentiation. EHNA also acts as a strong blocker of directed neuronal differentiation. Chemically distinct inhibitors of ADA and PDE2 lacked the capacity of EHNA to suppress hESC differentiation, suggesting that the effect is not driven by inhibition of either ADA or PDE2. Preliminary structure activity relationship analysis found the differentiation blocking properties of EHNA to reside in a pharmacophore comprised of a close adenine mimetic with an extended hydrophobic substituent in the 8-or 9-position. We conclude that EHNA and simple 9-alkyladenines can block directed neuronal and spontaneous differentiation in the absence of exogenous cytokine addition, and may provide a useful replacement for bFGF in large scale or cGMP compliant processes.
INTRODUCTION
Human embryonic stem cells (hESCs) can be maintained in an undifferentiated state whilst remaining capable of differentiating to all cell types in the body [1, 2] , as such, they have huge potential both as research tools and for cell therapies. In order to fully exploit this potential we must understand how to efficiently maintain hESCs in this self-renewing, pluripotent state. A large body of evidence indicates that the three transcription factors POU5F1, NANOG and SOX2 constitute the core transcriptional regulatory circuit that determines the fate of ESCs [3] [4] [5] [6] [7] . Expression levels of POU5F1/NANOG/SOX2 and their target genes are crucial in imposing stem cell identity and controlling differentiation [8] , and therefore it is critical for any culture system to maintain appropriate expression of this network. Methods to suppress spontaneous differentiation and maintain pluripotent hESCs vary greatly and utilise either feeder cells, feeder-conditioned media [9] or different combinations of cytokines (including high concentrations of bFGF [10, 11] , TGF-β/NODAL/ACTIVIN signalling molecules [12] [13] [14] or bone morphogenic protein (BMP) suppressors such as noggin [10, 15] ).
Small-molecule chemicals have been used in attempts to replace exogenous cytokines, in particular glycogen synthase kinase 3 beta (GSK3β) inhibitors, which stimulate the canonical Wnt/β-catenin axis, have been widely used to maintain pluripotency in mESC and in some hESC studies [16] . Additionally, Ying et al found that stimulation of cells by exogenous growth factors was not required for the maintenance of pluripotency in mouse ESCs, instead suppression of pro-differentiation signals -by inhibiting mitogen-activated protein kinase (MAPK), GSK-3β and FGF signaling -was sufficient to maintain self-renewal and pluripotency [17] . Thus, rather than using combinations of complex growth factors to stimulate self-renewal, protecting the cells from pro-differentiation factors or using small-molecule inhibitors of differentiation may provide viable alternatives for the maintenance of hESCs. Given the importance of the core transcriptional network in both maintaining and inducing pluripotency, the discovery of small molecules that can maintain the expression of these transcription factors, either in the presence of differentiation cues or in the absence of maintenance factors such as exogenous FGF, would be a valuable asset to the field and a further step towards unraveling the mechanisms of pluripotency.
Cyclic nucleotides are pivotal second messengers that influence a number of critical events including cell cycle and differentiation processes. Cyclic nucleotide phosphodiesterases (PDEs) provide the sole means of degrading cAMP and cGMP in cells with selective inhibitors shown to provide powerful reagents to manipulate specific cellular events and act as therapeutic agents [18] . With this in mind we analysed the effect of a range of inhibitors selective for major PDE families on hESC differentiation. From this we discovered that erythro -9-(2-hydroxy-3-nonyl) adenine (EHNA), an inhibitor of both the dual specificity cAMP/cGMP-phosphodiesterase, PDE2 [19] and adenosine deaminase (ADA) [20] , maintains the expression of hESC pluripotency markers even when cells are cultured under differentiating conditions. Moreover, EHNA also prevents differentiation and maintains pluripotency when exogenous FGF is removed from a supportive culture system. It thus provides a simple chemical entity that is capable of blocking the differentiation of hESCs.
EXPERIMENTAL

Cell culture and differentiation
The SA121 hES cell line [21] , (Cellartis AB, Dundee, UK) was cultured in feeder-free conditions on fibronectin and enzymatically passaged with TrypLE Select (Invitrogen). The fully supportive media used to maintain the hESCs was a 1:1 mixture of defined media [22] and conditioned VitrohES (VitroLife, Gothenburg, Sweden). VitrohES was conditioned for 24 h on mitotically inactivated mouse embryonic fibroblasts (MEF) with no addition of FGF. SA461 hES cells [21] (Cellartis AB) were maintained on MEFs and used to test whether EHNA supports the change from feeders to feeder-free To determine if prior adaptation to feeder-free conditions is required for EHNA to block the differentiation of hESCs in the absence of FGF, a culture of the hESC line SA461 was transferred directly from a supportive MEF feeder layer, using manual dissection, to NFE medium. After multiple passages the EHNA-containing cultures were still almost 100% positive for POU5F1 whereas POU5F1 staining in the cultures grown in NF medium was minimal ( Figure 1a ). This indicates that pre-adaptation to feeder-free conditions was not required for EHNA to block the differentiation of hESCs in the absence of FGF and that the effect of EHNA can be seen in a second hESC line..
Real time qRT-PCR analysis showed that at passage 8 in NF medium cells had greatly down-regulated the expression of NANOG, POU5F1 and SOX2 in comparison to hESCs grown in standard feederfree culture (containing FGF), or to cells grown with EHNA (NFE) (Figure 1c ). The NF-cultured cells also showed an increase in the expression of a variety of differentiation markers from multiple germ layers, particularly those associated with trophoectoderm formation (Supplemental Figure 1) . In contrast, EHNA (NFE medium) maintained an expression profile similar to that of cells in standard feeder-free culture and maintained that pattern for at least 30 passages (Supplemental Figure 2) .
Cells maintained in EHNA retain the capacity for in vitro differentiation to all three germ layers.
It is important that any component of stem cell medium that maintains a pluripotent phenotype does not permanently block differentiation of the cells. Therefore, to determine if chronic exposure to EHNA still allowed for subsequent differentiation, cells that had been in the EHNA-containing, NFE medium for either 10 passages (Figure 2 ) or >20 passages (Supplemental Figure 3 ) were allowed to differentiate passively. After 4 weeks cells were analysed for PAX6 (ectoderm), alpha-feta protein (AFP) (endoderm) and smooth muscle actin (SMA) (mesoderm) in order to detect differentiation to all three germ layers. Cells staining positive for three germ layers were readily detected (Figure 2 and Supplemental Figure 3 ). This indicates that, at least in vitro, cells grown in EHNA for over 10 passages retain functional pluripotency.
In order to understand whether pre-treatment with EHNA has any effect on the dynamics of induced, rather than spontaneous, differentiation cells that had been maintained in either EHNA or FGF for five passages were transferred into neuronal differentiation conditions [23] . Analysis over the time-course demonstrated that expression of PAX6 increased and NANOG decreased similarly in both EHNAtreated and control cultures, although we did observe that there was slight retardation of the NANOG down-regulation in EHNA-maintained cells (Figure 3a-b) . Immunofluorescent staining at the 16 day time point also indicated that cells grown previously on EHNA express PAX6 protein and downregulate POU5F1 (Figure 3c-d) .
EHNA maintains the expression of the core stem cell transcriptional factors in differentiating conditions. In order to test the direct effect of EHNA in maintaining pluripotent genes and blocking differentiation, cells maintained in full feeder-free media were subjected to neuronal differentiation conditions in the presence of various doses of EHNA throughout the neuronal differentiation. As illustrated in Figure 4a , EHNA caused a dose-dependent reduction in the proportion of cells staining positively for PAX6 with 10 µM EHNA completely eliminating PAX6. Additionally, qRT-PCR analysis (Figure 4b-e) , showed that the pluripotent markers NANOG, POU5F1 and ZFP42 were all maintained by the presence of EHNA. This ability of EHNA to block differentiation was sustained over at least 6 weeks of neuronal induction (Figure 4f ). Thus, EHNA exerts a dramatic antidifferentiation effect even in the presence of established differentiating conditions.
EHNA does not suppress hESC differentiation by inhibition of PDE2.
In order to investigate the basis for EHNA's anti-differentiation effect, we set out to exploit the capacity of EHNA to suppress passive differentiation in defined media. We evaluated the maintenance of NANOG and suppression of PAX6 expression as means of defining whether compounds with related enzyme-inhibitory activity to EHNA acted similarly on hESCs. In this regard, EHNA is an established inhibitor of both adenosine deaminase [20] and PDE2 [19, 25] . In order to evaluate whether the effect of EHNA was due to PDE2 inhibition, the specific PDE2 inhibitor, BAY-60-7550 6 (BAY) [26, 27] and the pan-cyclic nucleotide PDE inhibitor, [25], were each separately added to cultures undergoing passive differentiation (as above). In contrast to EHNA, treatment with neither BAY nor IBMX maintained stem cell marker expression in differentiating conditions ( Figure 5a ); nor did they inhibit PAX6 induction (Figure 5b ). This strongly suggests that PDE2 inhibition is not the mechanism whereby EHNA maintains hESC pluripotency.
EHNA does not suppress hESC differentiation by inhibition of adenosine deaminase. EHNA is also an established ADA inhibitor and, as such, it causes the accumulation of adenosine and deoxyadenosine, resulting in pleiotropic effects upon the cell [20, [28] [29] [30] [31] [32] . To determine whether the effects of EHNA are mediated by phosphorylated metabolites of adenosine, an adenosine kinase inhibitor, ABT-702 (AKI), was used in conjunction with EHNA. After 2 weeks under passive differentiation conditions the effects of EHNA were not reduced by the concurrent inhibition of adenosine kinase (Figure 5c ). Additionally, stimulation of AMPK with 5-aminoimidazole-4-carboxamide riboside (AICAR) did not mimic the effect of EHNA. Thus, we concluded that phosphorylation of adenosine is not necessary for the maintenance of pluripotency markers by EHNA.
Accumulation and export of adenosine and deoxyadenosine can, in principle, lead to activation of the adenosine receptors. To investigate whether adenosine receptor activation is responsible for the maintenance of hESC pluripotency markers by EHNA, we evaluated whether 5'-Nethylcarboxamidoadenosine (NECA), a pan-adenosine receptor agonist, and the non-selective PDE inhibitor and adenosine receptor antagonist, theophylline, could ablate the effect of EHNA. Neither agent, had any effect on the expression of hESC pluripotency markers in the presence or absence of EHNA (Figure 5c ). Similarly, targeting individual adenosine receptor subtypes with specific antagonists in addition to EHNA had no effect (Figure 5d ). Hence, adenosine receptor activity is unlikely to underpin EHNA's action on hESCs.
To further investigate whether the effect of EHNA might still be driven by ADA inhibition, we sourced or synthesised a panel of structurally diverse compounds ( Figure 6 ; Supplemental Figures 4 and 5) known to possess widely varying degrees of ADA-inhibitory activity. Critically, there was no correlation between ADA-inhibitory activity and the capacity of these compounds to maintain pluripotency-associated factors and to suppress PAX6 expression. Some compounds with potent ADA-inhibitory activity failed to show any EHNA-like effect. Pentostatin, an exceptionally potent ADA-inhibitor (K i = 2.5 pM for ADA) [33] , lacked any effect at concentrations of up to 100 µM even in combination with the PDE2 inhibitor, BAY-60-7550 (data not shown). Similarly, erythro-1-(2-hydroxynonan-3-yl)-1H-imidazole-4-carboxamide (HWC-36), an analogue of EHNA with a truncated adenine ring, showed no capacity to maintain NANOG or to suppress PAX6 expression at a concentration of 10 µM, despite possessing potent ADA-inhibitory action (K i = 35 nM vs 7 nM for EHNA) [34] . However, a series of 2-alkyl-2H-pyrazolo [3,4-d] pyrimidin-4-amine ADA inhibitors described by Da Settimo et al. [35] did exhibit EHNA-like maintenance activity. The octyl, nonyl, decyl and undecyl analogues in this series ( Figure 6 and Supplemental Figure 4 ; respectively HWC-41, HWC-31, HWC-06 and HWC-33), with reported ADA-inhibitory K i values of 530, 8.1, 0.13 and 0.47 nM, exhibited pronounced maintenance of the pluripotency marker, NANOG, coupled with a suppression of the differentiation marker, PAX6, when tested at 10 µM concentrations. Da Settimo et al [35] found the 1-alkyl-substituted isomers of their 2-alkylpyrazolopyrimidine series lacked significant ADA-inhibitory activity. However, we found that the octyl-and nonyl-analogues in the non-ADA-inhibitory 1-alkylpyrazolopyrimidine series (respectively HWC-40 and HWC-30) retained the differentiation-suppressive properties of their 2-alkyl isomers and of EHNA. As shown in Figure 7 , HWC-30, like HWC-31 and HWC-33, maintained the expression of pluripotency genes whilst suppressing PAX6. Collectively these data strongly suggest that the action of EHNA on hESCs is not driven by ADA inhibition.
To investigate the possibility that EHNA and other active compounds may act through a protein kinase-inhibitory mode, EHNA, HWC-5 and HWC-6 were evaluated using the Protein Kinase Panel service of the MRC National Centre for Protein Kinase Screening (University of Dundee, UK). When tested at 30 µM, none of these compounds significantly inhibited any of the 80 kinases of the panel 7 (Supplemental Figure 6 ). This included GSK-3β [16] , a number of ERK/MAPK pathway components [36] and FGF-R1 [37] , which have all previously been shown to be important in hESC pluripotency.
Structure activity relationships for the differentiation blocking activity of EHNA As EHNA did not appear to exert its action on hESCs through inhibition of either PDE2 or ADA, we undertook a preliminary structure activity relationship analysis by evaluating a wider set of EHNA analogues. The compounds assessed, Figure 6 (and detailed in full in the Supplemental Material) show that maintenance of NANOG and suppression of PAX6 requires a compound structure comprising a close adenine mimetic with an extended hydrophobic substituent in the 8-or 9-position. We found that the EHNA structure could be simplified by removal of the hydroxy group from the nonanol side chain, and deoxy-EHNA (HWC-57) retains activity comparable to EHNA itself. As a further step, we replaced the branched hydrocarbon chain of the latter compound with a straight chain n-decyl group to provide a compound [9-(decan-1-yl) adenine, HWC-64] that also retained the full action of EHNA on hESCs. In fact cells grown for 10 passages in FGF-free feeder-free conditions, but supplemented with either HWC-57 (10 µM) or HWC-64 (10 µM) show an equivalent morphology ( Figure 8a ) and gene expression pattern (Figure 8b ) to those grown in FGF-containing supportive media. Cells without either FGF or HWC-57/HWC-64 show a strong differentiated morphology by passage 4 (Figure 8a ). These data indicate that HWC-57 and HWC-64 are functionally equivalent to EHNA with regard to maintaining the markers of pluripotency in the absence of FGF.
The recently disclosed EHNA-ADA co-crystal structure reveals that its hydroxyl side chain contributes an important hydrogen bond to a histidine residue within the catalytic pocket [38] . The redundancy of this hydroxyl group in regard to the hESC differentiation blocking properties further supports the contention that this activity is not mediated through ADA inhibition. Thus, neither of the two established activities of EHNA, namely ADA inhibition and PDE2 inhibition, appear to be responsible for the maintenance of hESC pluripotency and suppression of differentiation. This implies a novel mechanism of action for which, although currently unidentified, we have provided preliminary structure activity relationships (SAR) by studying a range of EHNA analogues.
DISCUSSION
The regulation and maintenance of pluripotency in hESCs is still far from fully understood and there are multiple methods for cultivating hESCs in a pluripotent state. Traditionally hESCs have been cultivated on a mouse embryonic feeder layer [2] with further recent advances resulting in feeder-free culture systems on extracellular matrix proteins, which may be recombinant or extracted [10-12, 14, 15] . However, hESCs cultured in these feeder-free systems lack the mainly undefined stimuli from the feeder cells that maintain these cells in a self-renewing, pluripotent state and therefore, additional recombinant growth factors must be added to replace the contribution of the feeder cells. The only growth factor that has been shown to be essential for the maintenance of pluripotency in the absence of feeder-layers or conditioned media is basic FGF (bFGF, FGF-2) [10, 37] . However other factors, including TGFβ, are also commonly used to either remove or reduce the need for high concentrations of bFGF and/or conditioned media [12] [13] [14] . Such recombinant growth factors have a plethora of effects and, when considering the potential for using pluripotent cell-derived tissues in the clinic, are difficult to obtain from current good manufacturing practice-qualified sources. Simple small molecule alternatives to growth factors for maintaining pluripotent hESCs would not only be more amenable to current good manufacturing practice-compliant use, but are likely to provide powerful new tools for trying to uncover the molecular basis of pluripotency.
We have demonstrated here that the spontaneous differentiation of hESCs in the absence of either feeder cells or exogenous cytokines can be blocked by the addition of EHNA. We have also shown that EHNA is sufficiently supportive in that cells could be directly switched from feeders into feederfree culture without pre-adaptation to feeder-free culture containing exogenous FGF. Importantly, we found that chronic EHNA treatment did not 'lock' hESCs in an undifferentiated state, as the EHNAtreated cells were capable of multi-lineage differentiation when EHNA was removed. However, suppression of differentiation was sufficiently robust that when cells were switched into neuronal inducing conditions, the continued addition of EHNA blocked PAX6 expression and maintained the pluripotent morphology and the markers NANOG, POU5F1 and ZPF42. Furthermore, through our structure activity relationship analysis, we discovered that simple 9-alkyladenines, such as HWC-57 and HWC-64, possess activity comparable to EHNA. These robust, stable compounds are readily prepared from commercially available starting materials at low cost in just two synthetic steps, and, as such, offer a very attractive alternative to the use of bFGF in large scale applications.
EHNA has a number of reported effects including the inhibition of PDE2 [19] , but as we were unable mimic the effect of EHNA with either a structurally dissimilar PDE2 specific inhibitor [26] or the non-specific cyclic nucleotide PDE inhibitor IBMX [25] we can conclude that PDE2 inhibition does not account for the effect of EHNA in hESCs. EHNA has also been reported to reduce intracellular trafficking by inhibition of dynein. However, concentrations in the order of 100 µM are typically used for inhibiting dynein, because the EC 50 value for this lies between 0.23 mM and ~1 mM [39, 40] . As we used EHNA at a maximum concentration of 10 µM and see significant effects at 1 µM, we believe that it is unlikely that EHNA acts through effects on dynein in hESCs. The inhibition of ADA by EHNA was a particularly interesting possibility because a deficiency of ADA can cause a multitude of effects on the cell including apoptosis, the inhibition of transmethylation and an accumulation of adenosine that can subsequently lead to the activation of AMPK and adenosine receptors [30, 41] . We therefore investigated whether the ADA-inhibitory activity of EHNA was essential to its capacity to block differentiation in hESCs via the accumulation of adenosine and autocrine activation of cell-surface receptors, but we could not mimic the effect of EHNA using adenosine receptor agonists. Neither could we ablate the effect of EHNA with adenosine receptor antagonists. A build up of the phosphorylated metabolites of adenosine was also not responsible for the EHNA effect. To further investigate the possibility of ADA inhibition being responsible we used a panel of established adenosine deaminase inhibitors that are chemically distinct from EHNA, and clearly demonstrated (Figures 6 & 7) that there is no link between the two activities. This leads us to believe that EHNA has an unidentified biological activity that is responsible for its ability to prevent hESC differentiation.
It is an interesting proposition that EHNA may be able to maintain pluripotent marker expression by blocking differentiation. Ying et al. proposed that mESCs actually exist in a basal self-maintaining state that can be perpetuated if shielded from differentiation-inducing signals [17] . Unlike mESCs, many of the intracellular signalling pathways in hESCs are as yet unidentified. Nevertheless, it is probable that they are conceptually similar to mESCs in that pluripotency can be maintained if the differentiating signals are removed or blocked. Our data show that EHNA is an efficient blocker of induced neuronal differentiation and of other lineages generated as cells differentiate passively after the removal of bFGF. It should also be noted that although feeder-free, the culture system contains a conditioned medium component. Therefore, whilst EHNA is an effective replacement for exogenous bFGF there may be a combinatorial effect with other conditioning factors in the medium.
It is therefore possible that EHNA might be used to maintain hESCs in a self-renewing ground state, regulated by NANOG expression, as has been described for mESCs treated with inhibitors of both GSK-3β and MAPK [17, 42] . This hypothesis is supported by our finding that cells maintained in EHNA retained the expression of the core transcription factors NANOG, POU5F1 and SOX2 to the same degree as those maintained by bFGF, whereas in control cultures from which bFGF was omitted these factors were dramatically down-regulated. Initial reports suggested that GSK3β inhibitors may have the same capacity to maintain self-renewal in hESCs as in mESCs [16] . In order to exclude the possibility that EHNA was acting by directly inhibiting common protein kinase intracellular signalling pathways, we subjected the molecule to a protein kinase screen and found that it did not significantly inhibit any of the kinases evaluated, including GSK-3β, a number of ERK/MAPK pathway components and the FGF receptor, FGF-R1.
In summary, we have found that a small-molecule additive, EHNA, blocks the differentiation of hESCs in the absence of exogenous cytokines or feeder cells and can be used during routine enzymatic passage of the cells without the loss of multi-lineage differentiation potential. We have defined a pharmacophore for this action of EHNA, which is independent of its established PDE2-and ADAinhibitory activities, and identified simpler compounds that possess comparable activity. The capacity of EHNA and these derivates to block hESC differentiation may make them useful tools for the manipulation of hESCs and provide an important set of reagents for characterising pathways involved in the maintenance of pluripotency or suppression of differentiation in these cells. Antonini, I., Cristalli, G., Franchetti, P., Grifantini, M., Martelli, S., Lupidi, G. and Riva, F. Immunostaining is of POU5F1 (green), PAX6 (red) and DAPI (blue). Scale bars, 100µm. qRT-PCR analysis of (b) Nanog, (c) POUF51, (d) ZFP42, and (e) PAX6 expression was analysed throughout a neural differentiation with and without EHNA (10µM) present continually. (f) Expression of NANOG and PAX6 was analysed by qRT-PCR at 4 weeks and 6 weeks post neural differentiation induction. EHNA was either present throughout (+EHNA; 10 µM) or absent (-EHNA) from the differentiations (ND = neural differentiation). Data represents mean ± SEM from three experiments. For (a) and (b) the value 1 was set to level of expression in undifferentiated hESCS whereas in (c) and (d) the value 1 was set to the expression level in the untreated control samples. All other values were calculated respectively. EHNA -erythro-9-(2-hydroxy-3-nonyl)adenine (10 µM); IBMX -3-isobutyl-1-methylxanthine (100 µM); BAY -BAY-60-7550 (5 µM); AKI -adenosine kinase inhibitor (ABT-702) (5 µM), AICAR -5-aminoimidazole-4-carboxamide-1-ß-D-ribofuranoside (0.5 mM); NECA -adenosine-5'-N-ethylcarboxamide (10 µM), THEO -theophylline (10 µM); CPX -8-cyclopentyl-1,3-dipropylxanthine (10 µM), SCH -SCH 58261 (10 µM), M3 -MRS3777 (10 µM), M1 -MRS1754 (10 µM). Student t tests compared data between experimental groups. Asterisks indicate that cells treated with EHNA are statistically significant in comparison to the untreated control group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Figure 6 . The effect of known ADA inhibitors and related compounds on the expression of NANOG and PAX6 in SA121 hESCs under differentiation conditions. Compounds which maintained, after 14 days of differentiation, at least 50% of the level of NANOG-expression in comparison to EHNA and those that inhibited the expression of PAX6 to 50% or less than the value of the untreated controls were considered to have an EHNA-like effect. Those which had a single effect, to these levels, on either PAX6 or NANOG were considered to have a partial-EHNA effect. All compounds were tested at 10 µM. All compound structures are defined in the Supplementary Figure 4. [44-48] Figure 7 . The differentiation blocking effect of EHNA is not associated with adenosine deaminase inhibition. SA121 hESCs underwent passive differentiation for 14 days (with and without compound addition) and subsequently analysed by qRT-PCR. Data represents mean ± SEM from three experiments. Expression is relative to expression in the untreated control samples. adenine; HWC-57 -deoxy-EHNA; HWC-30 -2-nonyl-2H-pyrazolo [3,4-d] pyrimidin-4-amine hydrochloride; HWC-31 -1-nonyl-1H-pyrazolo [3,4-d] pyrimidin-4-amine hydrochloride; HWC-33 -1-undecyl-1H-pyrazolo [3,4-d] pyrimidin-4-amine hydrochloride; Pento -pentostatin. All compounds were used at 10 µM. Student t tests compared data between experimental groups. Asterisks indicate that cells treated with EHNA are statistically significant in comparison to the untreated control group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Structure Activity Relationship Commentary
In order to define the structural determinants of EHNA's capacity to suppress hESC differentiation we evaluated a range of structurally variant EHNA analogues. We also included in the test compound set a number of established ADA inhibitors with widely different inhibitory potencies in order to probe the potential contribution of ADA inhibition to EHNA's effects on stem cells.
Removal, replacement or N-substitution of the adenine 6-NH 2 group (as in compounds 2-10, Suppl. Fig. B1) significantly compromised the EHNA stem cell maintenance capacity. In principle, this might be consistent with an ADA-inhibitory mode of action, since the 6-NH 2 group of EHNA makes important contacts within the enzyme's catalytic pocket. Thus, the recently disclosed EHNA-ADA co-crystal structure (PDB: 2Z7G) reveals that the 6-NH 2 engages Asp296 (a residue that binds the protonated substrate N-7 centre) and networks to Glu217 by two hydrogen-bonded bridging water molecules, Suppl. Fig. B2 (a)/(b). 1
In contrast to the N-1, N-9 and 6-NH 2 centres of EHNA, which are all implicated in binding to ADA, the N-3 position makes no contact with the enzyme, Suppl. Fig. B2 (b). Consistent with this, the 3-deaza analogue (11) of EHNA reportedly possesses comparable ADA-inhibitory potency to EHNA itself. 2 We therefore tested compound 11, but found that its stem cell maintenance capacity was much reduced compared to EHNA.
It has further been shown that good ADA-inhibitory activity is retained in EHNA analogues where the pyrimidine ring C-2 and N-3 centres are elided. Thus, imidazole carboxamides 12 and 13 are effective ADA inhibitors (K i 368 nM and 35 nM respectively vs K i 7 nM for EHNA). 3 Co-crystal structures of related compounds (e.g. 14, Suppl. In contrast to pentostatin, another established ADA inhibitor, pyrazolopyrimidine 18a (K i 0.13 nM), 6 did exhibit a stem cell maintenance effect comparable to EHNA. The ADA inhibitory potency of pyrazolopyrimidines related to 18a is reportedly strongly dependent on both the length of the hydrocarbon chain and its site of attachment to the core heterocycle. Thus, for a series of 2-alkyl-2H-pyrazolo [3,4-d] pyrimidin-4-amines (16a-19a; K i 530, 8.1, 0.13 & 0.47 nM respectively) optimal ADA inhibition was seen with the n-decyl chain and inhibitory potency fell off markedly with truncation to n-octyl. 6 The isomeric 1-alkyl-1H-pyrazolo [3,4-d] pyrimidin-4-amines (16b-19b) were inactive or only very weakly active as ADA inhibitors. 7 In the ADA-inhibitory 2-substituted series we found the undecyl and nonyl homologues (17a and 19a) to have comparable stem cell maintenance activity to EHNA and 18a, though the octyl homologue (16a) was less effective. Unfortunately, poor solubility characteristics precluded assessment of the longer chain compounds (18b and 19b) in the non-ADA-inhibitory 1-substituted series. The shorter chain homologues 16b and 17b were amenable to assessment, however, and compound 17b, with the nonyl chain, was found to have a stem cell maintenance effect comparable to that of isomer 17a and to EHNA.
The octyl homologue (16b) was less active than EHNA, but comparable in activity to isomer 16a.
Collectively these data strongly suggested that ADA inhibition does not contribute to or is not the sole contributory factor responsible for EHNA's stem cell maintenance properties and that the key structural features required for 7 Only compounds 17b-19b were tested in the work described in Ref. 6 ; the octyl homologue (16b) was not reported.
B2
Chemistry activity are an intact adenine ring (or a close mimetic) together with a long hydrophobic 'tail', though the precise connection of the latter to the 5-membered ring shows some tolerance. The presence of the adenine N-7 nitrogen appears to be non-critical.
The activity of the pyrazolopyrimidine compounds (17-19) also suggested that the EHNA side chain hydroxyl might be superfluous. Before assessing this, however, we undertook the preparation and separate evaluation of the two
erthyro-EHNA enantiomers [(+)-EHNA, (2S,3R)-1 and (-)-EHNA (2R,3S)-1]
, Suppl. Fig. B1 , since the commercially supplied EHNA was racemic. Of these compounds, (2S,3R)-1 is the more potent ADA inhibitor (K i 0.76 nM vs 62 nM for the antipode) 8 and this isomer was also found to be markedly more effective than the enantiomer [(2R,3S) -1] in maintaining stem cell pluripotency. However, deoxy-EHNA (21), which was prepared in racemic form, did indeed show comparable activity to (rac)-EHNA itself. These data suggest that the hydroxyl in EHNA is merely tolerated in (2S,3R)-1 rather than beneficial and that its presence in the enantiomer [(2R,3S)-1] actually compromises activity.
The deoxy-EHNA analogue (22) with a shortened oct-3-yl side chain also showed similar levels of activity to EHNA itself.
The redundance of the EHNA hydroxyl group for hESC maintenance activity was a significant finding. This group assumes the position of the adenosine substrate 5'-OH and hydrogen bonds to His17 and Asp19 in the ADA catalytic pocket, Suppl. Fig. B2(b) , thereby making a significant contribution to the binding of the inhibitor. 9 The C. Baker and L. D. Hawkins, J Org Chem, 1982 , 47, 2179 -2184 It will be noted that strong ADA-inhibitory activity in the 2-alkyl-2H-pyrazolo [3,4-d] pyrimidin-4-amine series (16a-19a) does not require the hydroxylated side chain of EHNA. This likely reflects the adoption of a distinct but favourable ADA-binding mode by these compounds in which the adenine ring N-1 and 6-NH2 centres engage Asp296. Connection of the long side chain to the pyrazolopyrimidine N-1 position, as in the 1-alkyl-1H-pyrazolo [3,4-d] pyrimidin-4-amine series (16b-19b), would preclude adoption of this arrangement, requiring the compounds to dock in the EHNA-like mode. The absence of the branched hydroxylated EHNA side chain (and the adenine ring N-7 centre) severely compromises the binding affinity in this mode, however, thus accounting for the absent or very weak ADA-inhibitory activity in this series.
Suuplementary Figure B1
B3 Chemistry efficacy of deoxy-EHNA in the maintenance of stem cell pluripotency therefore further supports the contention that ADA inhibition does not mediate the action of these compounds on stem cells. Although the EHNA hydroxyl group is non-essential for stem cell maintenance activity, the compound's long hydrophobic side chain was found to be critical. Thus, the two methoxyethoxyethyl-substituted pyrazolopyrimidine isomers (20a/b), with shortened and more polar side chains, were significantly less active than EHNA or deoxy-EHNA (21). Moreover the EHNA analogue (23) with a truncated 2-hydroxyhex-3-yl side chain also showed a loss of activity. Interestingly, the activity was not restored by appending a phenyl substituent to the shortened chain of the latter, as in compound 24.
The size and character of the hydrophobic substituent commensurate with stem cell maintenance activity is therefore likely subject to constraints.
As a further simplification to the structure we assessed 9-(1-decyl)adenine (25) in order to remove the one remaining stereogenic centre in the deoxy-EHNA analogues 21/22. In contrast to EHNA, chemical synthesis of compounds 21 and 22 is very readily achieved in simple two-step sequences. The n-decyl analogue (25) is similarly readily prepared but has the advantage of being achiral. This simple robust compound showed a full stem cell maintenance effect comparable with the activity of the isosteric pyrazolopyrimidine (18b) and with that of EHNA itself.
Compound Synthesis General details
Commercially available reagents from Aldrich and Alfa Aesar chemical companies were generally used as supplied without further purification. Tetrahydrofuran (THF), diethyl ether and toluene were dried by distillation from sodiumbenzophenone ketyl under argon. 'Light petroleum' refers to the fraction boiling between 40 °C and 60 °C.
Anhydrous N,N-dimethylformamide (DMF) was purchased from Aldrich and used as supplied from Sure/Seal TM bottles. Reactions were routinely carried out under an inert atmosphere of argon or nitrogen. Analytical thin layer chromatography was carried out using aluminium backed plates coated with Merck Kieselgel 60 GF 254 (Art. 05554).
Developed plates were visualized under ultra-violet light (254 nm) and/or alkaline potassium permanganate dip. 
B4 Chemistry
Melting points were determined using a Stuart Scientific SMP10 apparatus and are uncorrected. IR spectra were recorded on a Perkin Elmer 1600 FT IR spectrometer. Spectra were recorded as potassium bromide discs, as 
racemic erythro-3-(6-mercapto-9H-purin-9-yl)nonan-2-ol (HWC-13)
A solution of erythro -3-(6-chloro-9H-purin-9-yl) nonan-2-ol was evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed by evaporation: (found: C, 50.27; H, 7.08; N, 16.76. C 14 H 22 N 4 OS/1.1 HCl requires C, 50.27; H, 6.96; N, 16 .75%).
racemic erythro-3-(6-methoxy-9H-purin-9-yl)nonan-2-ol (HWC-15)
A solution of erythro -3-(6-chloro-9H-purin-9-yl) nonan-2-ol 11 (150 mg, 0.505 mmol) and NaOMe (0.084 mL, 2.02 mmol) in anhydrous MeOH (10 mL) was heated at 70 °C for 2 h. TLC (1:2 light petroleum / EtOAc) indicated the transformation of starting material (R f 0.58) into product (R f 0.42). The reaction mixture was cooled, adjusted to pH 6 with acetic acid and evaporated. The residual solid was dissolved in water (10 mL) and extracted with CH 2 Cl 2 (20 mL) and EtOAc (20 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo to give a crude oil that was purified on a silica gel column (20 g). Elution with CH 2 Cl 2 / MeOH (96:4, 150 mL) gave erythro -3-(6-methoxy-9H-purin-9-yl) B5 Chemistry 14.13 (CH 3 ). erythro nonan-2-ol was evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed by evaporation.
racemic erythro-3-[6-(methylamino)-9H-purin-9-yl]nonan-2-ol (HWC-16)
A stirred mixture of erythro -3-(6-chloro-9H-purin-9-yl) nonan-2-ol 11 (208 mg, 0.701 mmol) and methylamine (33% w/w in ethanol; 14.0 mL) was heated at 100 °C in a heavy-walled sealed flask for 17 h. TLC (9:1 CH 2 Cl 2 / MeOH) indicated consumption of starting material (R f 0.53) and formation of a product component (R f 0.40). The reaction mixture was evaporated and the residue chromatographed on a silica gel column (25 g). Gradient elution with CH 2 Cl 2 / MeOH (98:2, 600 mL; 96:4, 100 mL) gave erythro-3- [6-(methylamino)-9H-purin-9-yl]nonan-2-ol (191 mg) as a pale yellow oil.
1
H NMR indicated the presence of minor impurities and the crude material was rechromatographed on a silica gel column (20 g). Elution with light petroleum:acetone (2:1, 300 mL) gave erythro-3- The reaction mixture was diluted with CH 2 Cl 2 (50 mL) and washed with saturated sodium bicarbonate solution (3 x 10 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated in vacuo to give a pale yellow oily which was chromatographed on a silica gel column (25 g). Gradient elution with light petroleum / EtOAc (3:1, 400 mL; 2:1, 300 mL; 1:1, 200 mL) gave erythro -3-(6-chloro-8-methyl-9H-purin-9-yl) chain CH 3 -1), m), 0.74 (3 H, approx. t, J 6.5, 
racemic erythro-3-(6-Amino-8-methyl-9H-purin-9-yl)nonan-2-ol (HWC-24)
A solution of erythro -3-(6-chloro-8-methyl-9H-purin-9-yl) nonan-2-ol (97 mg, 0.31 mmol) in ammonia 7 N in MeOH (10 mL) was stirred at 120 °C in a heavy-walled sea led tube for 18 h. TLC (95:5 CH 2 Cl 2 / MeOH) indicated the starting material (R f 0.44) was transformed into a minor product (R f 0.26) and a major product at (R f 0.12). The reaction mixture was concentrated in vacuo to give a light brown residue that was chromatographed on a silica gel column (20 g). Gradient elution with CH 2 Cl 2 / MeOH (98:2, 200 mL; 96:4, 200 mL) gave erythro-3-(6-amino-8- erythro nonan-2-ol was evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed by evaporation.
racemic erythro-3-[6-(methylthio)-9H-purin-9-yl]nonan-2-ol (HWC-25)
Sodium thiomethoxide (71 mg, 1.0 mmol) was added to a stirred solution of erythro -3-(6-chloro-9H-purin-9- yl)nonan-2-ol 11 (150 mg, 0.505 mmol) in a mixture of DMF (3 mL) and water (1 mL) at 0 °C. The mixture was allowed to attain room temperature and stirred for 3 h. TLC (9:1 CH 2 Cl 2 / MeOH) indicated consumption of starting material (R f 0.53) and formation of product (R f 0.60). The reaction mixture was diluted with EtOAc (50 mL) and then washed successively with water (15 mL), saturated sodium bicarbonate solution (15 mL) and brine (15 mL).
The organic phase was dried over Na 2 SO 4 , filtered and evaporated to give a dense colourless oil that was chromatographed on a silica gel column (10 g). Gradient elution with CH 2 Cl 2 / MeOH (99:1, 100 mL; 98:2, 100 mL) gave partially purified product (152 mg) that was re-chromatographed on a silica gel column (10 g). Gradient elution with CH 2 Cl 2 / MeOH (99:1, 100 mL, 98:2, 100 mL) gave erythro -3-[6-(methylthio)-9H-purin-9-yl] -3-(7-amino-3H-[1,2,3] triazolo [4,5-d] H, m), 1.32 (3 H, d, J 6.4, m), m), 0.84 (3 H, approx. t, J 6.5, -3-(7-amino-3H-[1,2,3] triazolo [4,5-d] pyrimidin-3-yl)nonan-2-ol was evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed by evaporation: (found: C, 47.60; H, 7.62; N, 25.54. C 13 racemic erythro-3-(6-hydrazinyl-9H-purin-9-yl)nonan-2-ol (HWC-27)
A mixture of erythro -3-(6-chloro-9H-purin-9-yl) nonan-2-ol 11 (210 mg, 0.708 mmol) and hydrazine hydrate (0.344 mL) in ethanol (7.0 mL) was refluxed at 85 °C for 20 h. TLC ( -3-(6-hydrazinyl-9H-purin-9-yl) 15 -4.11 (2 H, m), 3.78 -3.75 (2 H, m), 3.60 -3.56 (2 H, m), 3.49 -3.46 (2 H, m), 3.32 (3 H, s) elution with CH 2 Cl 2 / MeOH (98:2, 250 mL; 95:5, 250 mL) gave an oil (600 mg). The partially purified oil was dissolved in EtOAc (100 mL) and washed with water (3 x 15). The organic phase was dried over Na 2 SO 4 , filtered B8 Chemistry and concentrated in vacuo to give 1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazolo [3,4-d] MAP2  MYOD1  NANOG  NKX2-5  NUBP1  PAX6  PECAM1  RUNX2  SOX15  SOX17  SOX2  T  TDGF1  TEK  TERT  TUBB3  VGF 
1-octyl-1H
